➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Express Scripts
Mallinckrodt
McKinsey
Harvard Business School

Last Updated: July 3, 2020

DrugPatentWatch Database Preview

Patent: 9,994,615

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,994,615
Title:Self-regulated peptide hydrogel for insulin delivery
Abstract: A glucose binding amphiphilic peptide hydrogel insulin delivery system that is responsive to glucose concentrations under physiological conditions is provided. Insulin is encapsulated in a glucose binding hydrogel, made from self-assembling amphiphilic peptides including a hydrophobic domain including a beta sheet forming region coupled to a charged hydrophilic domain modified to contain a glucose binding segment. The formulations are designed to release insulin as a function of blood glucose level, maintaining the patients\' blood glucose level in an optimum range and avoiding both hyper- and hypoglycemia.
Inventor(s): Langer; Robert S. (Newton, MA), Anderson; Daniel G. (Sudbiry, MA), Gu; Zhen (Cambridge, MA), Aimetti; Alex Arthur (Waltham, MA)
Assignee: Massachusetts Institute of Technology (Cambridge, MA) The Children\'s Medical Center Corporation (Boston, MA)
Application Number:14/379,477
Patent Claims:see list of patent claims

Details for Patent 9,994,615

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Sanofi-aventis Us ADMELOG insulin lispro SOLUTION;INTRAVENOUS, SUBCUTANEOUS 209196 003 2018-10-19   Start Trial Massachusetts Institute of Technology (Cambridge, MA) The Children\'s Medical Center Corporation (Boston, MA) 2032-02-17 RX search
Sanofi-aventis Us ADMELOG SOLOSTAR insulin lispro SOLUTION;INTRAVENOUS, SUBCUTANEOUS 209196 002 2018-10-19   Start Trial Massachusetts Institute of Technology (Cambridge, MA) The Children\'s Medical Center Corporation (Boston, MA) 2032-02-17 RX search
Sanofi-aventis Us ADMELOG insulin lispro SOLUTION;INTRAVENOUS, SUBCUTANEOUS 209196 001 2018-10-19   Start Trial Massachusetts Institute of Technology (Cambridge, MA) The Children\'s Medical Center Corporation (Boston, MA) 2032-02-17 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Harvard Business School
Boehringer Ingelheim
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.